Michael B Lilly

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
    Matthew R Janes
    Department of Molecular Biology and Biochemistry, Institute for Immunology, University of California Irvine, Irvine, California, USA
    Nat Med 16:205-13. 2010
  2. ncbi Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75
    Melanie Mediavilla-Varela
    Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
    Mol Cancer 8:68. 2009
  3. ncbi Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
    Michael B Lilly
    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, USA
    Am J Hematol 85:164-70. 2010
  4. ncbi Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins
    Kimberly Romero Rosales
    Department of Developmental and Cell Biology, University of California, Irvine, CA 92697, USA
    Biochem J 439:299-311. 2011
  5. ncbi Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
    Michael G Kharas
    Department of Molecular Biology and Biochemistry, Center for Immunology, University of California, Irvine, Irvine, California, USA
    J Clin Invest 118:3038-50. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
    Matthew R Janes
    Department of Molecular Biology and Biochemistry, Institute for Immunology, University of California Irvine, Irvine, California, USA
    Nat Med 16:205-13. 2010
    ..These findings establish that Ph(+) transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy...
  2. ncbi Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75
    Melanie Mediavilla-Varela
    Center for Health Disparities and Molecular Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA
    Mol Cancer 8:68. 2009
    ..This knowledge is important for circumventing HRPC chemoresistance and reducing disparities in prostate cancer mortality...
  3. ncbi Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study
    Michael B Lilly
    Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, USA
    Am J Hematol 85:164-70. 2010
    ..Compared with the 70 mg twice daily, dasatinib 140 mg once daily had similar overall efficacy and safety in patients with imatinib-resistant or intolerant Ph+ ALL. (clinicaltrials.gov identifier: NCT00123487)...
  4. ncbi Sphingolipid-based drugs selectively kill cancer cells by down-regulating nutrient transporter proteins
    Kimberly Romero Rosales
    Department of Developmental and Cell Biology, University of California, Irvine, CA 92697, USA
    Biochem J 439:299-311. 2011
    ....
  5. ncbi Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells
    Michael G Kharas
    Department of Molecular Biology and Biochemistry, Center for Immunology, University of California, Irvine, Irvine, California, USA
    J Clin Invest 118:3038-50. 2008
    ..Our findings provide mechanistic insights into PI3K dependency in oncogenic networks and provide a rationale for targeting class IA PI3K, alone or together with mTOR, in the treatment of Ph+ ALL...